2024/11/01 12:30:40 | |
---|---|
Price | |
17.20 EUR | |
Difference | 0.58% (0.10) |
ISIN | JP3546800008 |
Symbol | 4543 |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 25,918 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | 17.20 EUR (180) |
Ask (Ask size) | 17.70 EUR (180) |
Open | 17.00 EUR |
High | 17.20 EUR |
Low | 17.00 EUR |
Close (prev. day) | 17.10 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 3 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/10/29 | Global Equity Ratings | ||
2024/10/29 | Aktienempfehlungen Global | ||
2024/10/22 | Global Equity Ratings | ||
2024/10/22 | Aktienempfehlungen Global | ||
2024/10/14 | Aktienempfehlungen Österreich |
2024/11/01 12:30:40 | |
---|---|
Price | |
17.20 EUR | |
Difference | 0.58% (0.10) |
ISIN | JP3546800008 |
Symbol | 4543 |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 25,918 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | 17.20 EUR (180) |
Ask (Ask size) | 17.70 EUR (180) |
Open | 17.00 EUR |
High | 17.20 EUR |
Low | 17.00 EUR |
Close (prev. day) | 17.10 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 3 |
Last size | 0 |
6M | 1Y | 3Y | |
Perf (%) | +8.92% | +33.59% | -9.43% |
Perf (abs.) | +1.40 | +4.30 | -1.78 |
Beta | 1.03 | 1.02 | 1.00 |
Volatility | 33.27 | 29.54 | 29.22 |
Ø price 5 days | Ø volume 5 days (pcs.) | 17.32 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 17.27 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 16.28 EUR (0) |
Ø price 250 days | Ø volume 250 days (pcs.) | 15.90 EUR (0) |
YTD High | date | 18.50 EUR (2024/03/04) |
YTD Low | date | 13.70 EUR (2024/08/05) |
52 Weeks High | date | 18.50 EUR (2024/03/04) |
52 Weeks Low | date | 12.70 EUR (2023/11/10) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/10/31 | 22:26 | 17.50 EUR | 0.00 | 1 |
Tokyo Stock Exchange | 2024/11/01 | 07:00 | 2,886.50 JPY | 113.69 | 7,425 |
Stuttgart | 2024/11/01 | 08:13 | 17.10 EUR | 0.00 | 1 |
Munich | 2024/11/01 | 08:03 | 17.50 EUR | 0.00 | 1 |
Hanover | 2024/11/01 | 08:01 | 17.10 EUR | 0.00 | 1 |
Frankfurt | 2024/11/01 | 08:10 | 17.10 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/10/31 | 16:05 | 18.384 USD | 0.03 | 13 |
Duesseldorf | 2024/11/01 | 12:30 | 17.20 EUR | 0.00 | 3 |
Berlin | 2024/11/01 | 08:03 | 17.10 EUR | 0.00 | 1 |
TERUMO CORP. |
- - |
2-44-1 Hatagaya, Shibuya-Ku - 151-0072 Tokyo |
Telefon: +81-3-3374-8111 |
Fax: + |
E-mail: kouhou_terumo01@terumo.co.jp |
Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan. |
Shinjiro Sato | Chairman of Managing Board |
Antoinette Gawin | Member of Executive Committee |
Fumihisa Hirose | Member of Executive Committee |
Hiraku Samejima | Member of Executive Committee |
Kazunori Hirose | Member of Executive Committee |
Norimasa Kunimoto | Member of Executive Committee |
Shoji Hatano | Member of Executive Committee |
Toshiaki Takagi | Member of Executive Committee |
Toshihiko Osada | Member of Executive Committee |
Toshiaki Takagi | Chairman of Supervisory Board |
Hidenori Nishi | Member of Supervisory Board |
Keiya Ozawa | Member of Supervisory Board |
Kyo Nishikawa | Member of Supervisory Board |
Masaichi Nakamura | Member of Supervisory Board |
Shinjiro Sato | Member of Supervisory Board |
Shouji Hatano | Member of Supervisory Board |
Soichiro Uno | Member of Supervisory Board |
Takanori Shibazaki | Member of Supervisory Board |
Yukiko Kuroda | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.